Linear regression models assessing the relation between the time before diagnosis and levels of inflammatory biomarkers showed a statistically significant decline in albumin levels (r square 0.164; P = .040) and a rise of CRP levels (r square 0.163; P = .041) in the preclinical phase for the patients that developed CD. This evidence concerns the gene ALB and Cowden disease.